Peter Flynn
SVP,
Head of Development, Regulatory Affairs and Safety
Orexigen
Australia
Biography
Peter Flynn joined Orexigen in 2015 and leads global development, regulatory and safety. Pete has over 15 years of biotechnology industry experience. Previously, Pete was Senior Vice President, Early Program Development at Fate Therapeutics, where he was responsible for development of programs and platforms and was a member of the senior team that took the company through an IPO in 2013. Prior to Fate he was Vice President of Research at Ren Pharmaceuticals. Pete started his industry career as one of the first employees at the antibody therapeutics company KaloBios Pharmaceuticals, where as head of biochemistry he helped build both the platform technology and pipeline. Pete holds a BSc in Molecular Biology from University College London, a Ph.D in Biochemistry from Imperial Cancer Research Fund (CRUK) and was a postdoctoral fellow at the University of California, San Francisco.
Research Interest
Molecular Biology and Molecular Genetics
